This bill creates an independent office of the ombudsperson for behavioral health access in New York. The ombudsperson will directly assist New Yorkers - especially those who are uninsured, underinsured, or navigating complex coverage - with resolving issues related to mental health and substance use disorder care access, including complaints about insurers or providers. Key provisions include the ombudsperson operating autonomously (with independent hiring and budget control), helping consumers file appeals, tracking violations of treatment rules, and reporting annually to state officials on access challenges. The office will not make policy changes but will serve as a neutral resource to navigate existing systems and connect people to appropriate support.
Authorizes certain facilities to provide treatment for the mental health and health care needs of individuals admitted for a substance use disorder; provides that such services shall be reimbursable by Medicaid and private insurance.
This bill requires health insurance plans in New York to cover postpartum pelvic floor physical therapy as part of mandatory maternity care. It directly affects new mothers by ensuring their health insurance must include this specific therapy to aid recovery after childbirth. The bill amends existing insurance law to add "postpartum pelvic floor physical therapy" to the list of required benefits, alongside services like breastfeeding support and newborn assessments. The policy change applies to all insurance contracts issued or renewed on or after its effective date.
Prevents discrimination by insurers based on an individual's mental health or substance use disorder; incorporates into law federal enforcement rules set forth in the federal mental health parity and addiction equity act of 2008.
Requires health insurers to provide coverage without cost-sharing for opioid antagonists and devices; provides that no prior authorization of premedical review for coverage of such opioid antagonist is required.
This bill requires all prescription containers for opioid medications to have a red cap top displaying the warning "Caution: OPIOID. Risk of overdose and addiction." It directly affects pharmacies dispensing opioids by mandating this specific container labeling. The key mechanism specifies that containers must use a red cap (or red stickers if caps are unavailable) with the exact warning text, replacing existing color-coded labeling requirements for controlled substances. This policy change aims to increase visible safety warnings at the point of prescription.
Bill A 8055 proposes to change how outpatient mental health and substance use disorder services are administered under Medicaid. It shifts these services, along with comprehensive Medicaid case management, from a managed care model back to a fee-for-service system. This change, subject to federal approval, directly affects individuals with mental illness or substance use disorder who rely on these services and the licensed facilities that provide them. The bill also requires that any savings generated by this transition be reinvested into community-based behavioral health services.
This bill requires healthcare providers distributing Schedule II opioids (like oxycodone or fentanyl) to include an informational card and fentanyl test strips with each prescription. The card must explain overdose symptoms, steps to take after using an opioid antagonist (including calling emergency services), addiction support resources, safe disposal methods, and how to access the state's addiction support hotline and website. It also mandates that materials be available in languages other than English as needed. This applies directly to pharmacies, hospitals, and medical programs distributing these high-risk medications, aiming to improve patient safety and overdose response.
Bill S 3185 mandates that health insurance policies covering pain management services must also provide outpatient coverage for non-opioid treatments for chronic pain, defined as pain lasting over three months. This directly affects individuals with chronic pain by expanding their covered treatment options to include complementary and integrative therapies. The bill ensures that insurance companies cannot impose stricter financial requirements or treatment limitations on non-opioid chronic pain treatments than they do for other medical benefits or for opioid-based pain treatments. This aims to provide comparable access and coverage for these non-opioid alternatives.
Prohibits nursing homes and care facilities that are registered with the state of New York and registered with the federal Drug Enforcement Agency, that maintains a stock of, and directly dispenses, controlled substance medications from denying admission to individuals receiving a controlled substance medication for a substance use disorder.